Logo
    Home > Topics > asrs

    asrs

    Explore " asrs" with insightful episodes like "What’s Next PanOptica? We Ask CEO Chaney", "ExSight Capital, Partner Firas Rahhal, MD, Are Building a Successful Record as Impact Investor", "Dr. Pravin Dugel Picks Possible Winners in Race to Deliver New Retinal Treatments", "Hatteras’ Shaffer Found a Model That Works at Inspire; Now She Uses It When Making Investments" and "Digital Health Is Dead? Don’t Tell Mark Blumenkranz, the FDA, or the Organizers of an Oct. Workshop" from podcasts like ""OIS Podcast | Ophthalmology's leading Podcast", "OIS Podcast | Ophthalmology's leading Podcast", "OIS Podcast | Ophthalmology's leading Podcast", "OIS Podcast | Ophthalmology's leading Podcast" and "OIS Podcast | Ophthalmology's leading Podcast"" and more!

    Episodes (42)

    ExSight Capital, Partner Firas Rahhal, MD, Are Building a Successful Record as Impact Investor

    ExSight Capital, Partner Firas Rahhal, MD, Are Building a Successful Record as Impact Investor
    With $3 million to invest in first-time funds, impact investor ExSight Capital built a promising and productive portfolio that included gene therapy company RetroSense. Now, ExSight co-founder and partner Firas M. Rahhal, MD, says the firm is planning to raise a much larger fund that could elevate its standing as a seed-stage investor in ophthalmology companies.
    OIS Podcast | Ophthalmology's leading Podcast
    en-usOctober 04, 2017
    healthcare
    innovation
    entrepreneurs
    venture capital
    investing

    Dr. Pravin Dugel Picks Possible Winners in Race to Deliver New Retinal Treatments

    Dr. Pravin Dugel Picks Possible Winners in Race to Deliver New Retinal Treatments
    Pravin Dugel, MD, managing partner, Retinal Consultants of Arizona, delivers a frank overview of the pipeline of experimental retinal drugs. The next year could be critical for retinal disease as combination therapies and other products push through late-stage clinical trials. What technologies show the most promise? What advances have surprised even him?
    OIS Podcast | Ophthalmology's leading Podcast
    en-usSeptember 28, 2017
    healthcare
    innovation
    entrepreneurs
    venture capital
    investing

    Hatteras’ Shaffer Found a Model That Works at Inspire; Now She Uses It When Making Investments

    Hatteras’ Shaffer Found a Model That Works at Inspire; Now She Uses It When Making Investments
    Christy Shaffer, PhD, general partner at Hatteras Venture Partners, didn’t have a career map that led her into the corner office at Inspire Pharmaceuticals or into the partnership at Hatteras Venture Partners. But the clinical scientist grew to succeed in both roles. Dr. Shaffer led Inspire when the company conceived and then built out its ophthalmology program, a business that trained many of today’s ophthalmology leaders. That experience still serves her today as she funds entrepreneurs and start-ups inside and outside of ophthalmology.
    OIS Podcast | Ophthalmology's leading Podcast
    en-usSeptember 20, 2017
    healthcare
    innovation
    entrepreneurs
    venture capital
    investing

    Digital Health Is Dead? Don’t Tell Mark Blumenkranz, the FDA, or the Organizers of an Oct. Workshop

    Digital Health Is Dead? Don’t Tell Mark Blumenkranz, the FDA, or the Organizers of an Oct. Workshop
    Accomplished ophthalmologist Mark Blumenkranz, MD, moved early into the Digital Health space by co-founding Digisight, one of the more advanced efforts in ophthalmology. Six years, later, Dr. Blumenkranz still sees enormous opportunity so he’s working with the FDA and top clinical societies to hold a one-day workshop for physicians, investors, and entrepreneurs interested in learning how Digital Health fits into ophthalmology.
    OIS Podcast | Ophthalmology's leading Podcast
    en-usSeptember 13, 2017
    healthcare
    innovation
    entrepreneurs
    venture capital
    investing

    What Was the Most Difficult Part of Successfully Transitioning to CMO? We Ask B&L’s Cal Roberts

    What Was the Most Difficult Part of Successfully Transitioning to CMO? We Ask B&L’s Cal Roberts
    In 2011, Cal Roberts, MD, got an unexpected call from Brent Saunders, then head of Bausch & Lomb. Saunders asked if Dr. Roberts would trade a thriving ophthalmology practice to serve as chief medical officer at the eye care giant. Today, Dr. Roberts is thrilled with the decision, and other ophthalmology companies are following the example, bringing on practicing physicians as CMOs. But what were Dr. Roberts’ concerns? And why did he decide to take the leap? “It’s difficult and it’s sometimes more difficult than someone coming in realizes,” he says.
    OIS Podcast | Ophthalmology's leading Podcast
    en-usSeptember 06, 2017
    healthcare
    innovation
    entrepreneurs
    venture capital
    investing

    Imperial College’s Dr. Cordeiro Explains How DARC May Bring Early Light to Disease, Shorten Trials

    Imperial College’s Dr. Cordeiro Explains How DARC May Bring Early Light to Disease, Shorten Trials
    M. Francesca Cordeiro, MD, PhD, professor, UCL and Imperial College London, Western Eye Hospital London, shares details of the institute’s detection of apoptosing retinal cells (DARC) scan – which employs a new retinal biomarker. The DARC system, which will undergo further trials, could allow for earlier detection of retinal disease in patients, as at least 30% to 50% of ganglion cells may be lost before vision is damaged. This test could be used to hone clinical trial endpoints of ophthalmology drugs, but it also may be used to detect neurological disease such as Parkinson’s and dementia.
    OIS Podcast | Ophthalmology's leading Podcast
    en-usAugust 28, 2017
    healthcare
    innovation
    entrepreneurs
    venture capital
    investing

    Why Did Charles Semba, MD, Switch Specialties and How Did He Find a Home in Ophthalmology?

    Why Did Charles Semba, MD, Switch Specialties and How Did He Find a Home in Ophthalmology?
    Charles Semba, MD, is one of the more recognized and accomplished figures in development of new ophthalmology treatments. He has played integral roles in the development of Lucentis, Xiidra, and more recently Forsight IV’s drug delivery technology. Now the chief medical officer at Graybug Vision, Dr. Semba is working to develop a technology that could significantly reduce the number of injections needed to deliver drugs to the back and front of the eye. But how did Dr. Semba, who had been a world renowned vascular specialist, run out such a string of successes in ophthalmology? And what is the biggest regret of his accomplished career?
    OIS Podcast | Ophthalmology's leading Podcast
    en-usAugust 23, 2017
    healthcare
    innovation
    entrepreneurs
    venture capital
    investing

    OIS@ASRS Co-Chairs Give High Marks and Hopes for Innovators Looking at the Back of the Eye

    OIS@ASRS Co-Chairs Give High Marks and Hopes for Innovators Looking at the Back of the Eye
    OIS@ASRS co-chairs Emmett Cunningham Jr., MD, Mark S. Humayun, MD, PhD, and John Pollack, MD, took a few minutes to share their thoughts on the second OIS@ASRS. Dr. Humayun, the outgoing ASRS president, shares details on his next undertaking – finding a way to measure the value of vision protection. Meanwhile, Dr. Pollack highlights one of his priorities after taking over as ASRS president.
    OIS Podcast | Ophthalmology's leading Podcast
    en-usAugust 16, 2017
    healthcare
    innovation
    entrepreneurs
    venture capital
    investing

    What Does TearScience Deal Mean for J&J? Group Chair Ashley McEvoy Shines Light on Future Plans

    What Does TearScience Deal Mean for J&J? Group Chair Ashley McEvoy Shines Light on Future Plans
    Last week, Johnson & Johnson announced plans to acquire TearScience, maker of a line of products capable of diagnosing and treating Meibomian gland dysfunction, a leading cause of Dry Eye. Ashley McEvoy , Company Group Chairman for Johnson & Johnson Vision, explains where TearScience will fit into J&J if the deal is completed and what the global giant’s plans for additional Dry Eye treatments may be.
    OIS Podcast | Ophthalmology's leading Podcast
    en-usAugust 08, 2017
    healthcare
    innovation
    entrepreneurs
    venture capital
    investing

    Allegro’s Poised to Deliver Positive News at ASRS; Could an IPO Be Next? We Ask Vicken Karageozian

    Allegro’s Poised to Deliver Positive News at ASRS; Could an IPO Be Next? We Ask Vicken Karageozian
    Allegro Ophthalmics expects to deliver some positive news about its Phase II DEL MAR trial that is evaluating the safety and efficacy of Luminate as an adjunctive therapy with anti-VEGFs in patients with diabetic macular edema (DME). Could the news put the company in a position for an initial public offering?
    OIS Podcast | Ophthalmology's leading Podcast
    en-usAugust 02, 2017
    healthcare
    innovation
    entrepreneurs
    venture capital
    investing

    Sun Pharma’s St. Peter Outlines Company’s Ambitious Plan to Build Ophthalmology Pipeline

    Sun Pharma’s St. Peter Outlines Company’s Ambitious Plan to Build Ophthalmology Pipeline
    Jerry St. Peter, VP & head, ophthalmic business, says the ophthalmology newcomer is making great progress in building a broad pipeline to treat eye disease including dry eye and ocular pain. In this interview he reviews several acquisitions and partnerships the company has made over the past 24 months.
    OIS Podcast | Ophthalmology's leading Podcast
    en-usJuly 11, 2017
    healthcare
    innovation
    entrepreneurs
    venture capital
    investing

    Donnenfeld Discusses How New Diagnostics, Treatments Impact His Practice and Patients

    Donnenfeld Discusses How New Diagnostics, Treatments Impact His Practice and Patients
    Eric Donnenfeld, MD, founding partner of OCLI, shares how his practice is incorporating new diagnostics and treatments. “I spend less time diagnosing the disease and it enables me to spend more time talking to the patients about therapies,” Dr. Donnenfeld says. He also praises Shire and Allergan for their effective marketing.
    OIS Podcast | Ophthalmology's leading Podcast
    en-usJune 07, 2017
    healthcare
    innovation
    entrepreneurs
    venture capital
    investing
    Logo

    © 2024 Podcastworld. All rights reserved

    TwitterYouTubeInstagramPinterestFacebookLinkedIn

    Pages

    PodcastsEpisodesTopics

    Support

    Refund PolicyTerms of ServiceContact usPrivacy Policy

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io